Last reviewed · How we verify
Metformin plus chemotherapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Metformin plus chemotherapy (Metformin plus chemotherapy) — Hager salah el din.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Metformin plus chemotherapy TARGET | Metformin plus chemotherapy | Hager salah el din | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Metformin plus chemotherapy CI watch — RSS
- Metformin plus chemotherapy CI watch — Atom
- Metformin plus chemotherapy CI watch — JSON
- Metformin plus chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Metformin plus chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-plus-chemotherapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing